Etanercept and infliximab for the treatment of psoriatic arthritis

NICE technology appraisals [TA104] Published date:

This guidance has been replaced by TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab

  • Erratum

    Please note that there is a minor discrepancy between the electronic version of the ‘quick reference guide’ (QRG) on the NICE website and the hard copy version that was mailed to the NHS to arrive on Wednesday 26 July. Section 1.3 of the guidance should read as follows:

    1.3 Infliximab, within its licensed indications, is recommended for the treatment of adults with severe active psoriatic arthritis if, under the circumstances outlined in section 1.1, treatment with an anti-TNF (tumour necrosis factor) agent is considered appropriate and the person has been shown to be intolerant of, or have contraindications to, treatment with etanercept or has major difficulties with self administered injections.

    The electronic version of the QRG that has been published on the NICE website is the correct version. A follow-up mailing to the NHS explaining this error and enclosing a hard copy of the correct version of the QRG will be sent out shortly.

  • Get involved